Corcept Therapeutics plans to price a public sale of its common stock

Deal offers 11 million shares with a greenshoe of 1.65 million shares

By Devika Patel

Knoxville, Tenn., July 2 - Corcept Therapeutics Inc. said it plans to price a public sale of stock with a 30-day greenshoe.

The company will sell 11 million common shares, with 1.65 million shares allotted for the greenshoe.

Credit Suisse Securities (USA) LLC is the bookrunning manager.

Proceeds will be used for research and development activities, including clinical trials, working capital and general corporate purposes.

Menlo Park, Calif.-based Corcept is a pharmaceutical company engaged in the development of medications for the treatment of severe psychiatric and metabolic diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.